CA3045491A1 - Integrin antagonists - Google Patents

Integrin antagonists Download PDF

Info

Publication number
CA3045491A1
CA3045491A1 CA3045491A CA3045491A CA3045491A1 CA 3045491 A1 CA3045491 A1 CA 3045491A1 CA 3045491 A CA3045491 A CA 3045491A CA 3045491 A CA3045491 A CA 3045491A CA 3045491 A1 CA3045491 A1 CA 3045491A1
Authority
CA
Canada
Prior art keywords
compound
unsubstituted
substituted
integrin
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3045491A
Other languages
English (en)
French (fr)
Inventor
Peter G. Ruminski
David W. Griggs
Scott Seiwert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indalo Therapeutics Inc
Saint Louis University
Original Assignee
Indalo Therapeutics Inc
Saint Louis University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indalo Therapeutics Inc, Saint Louis University filed Critical Indalo Therapeutics Inc
Publication of CA3045491A1 publication Critical patent/CA3045491A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
CA3045491A 2016-12-29 2017-12-28 Integrin antagonists Abandoned CA3045491A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662440253P 2016-12-29 2016-12-29
US62/440,253 2016-12-29
US201762471882P 2017-03-15 2017-03-15
US62/471,882 2017-03-15
PCT/US2017/068801 WO2018132268A1 (en) 2016-12-29 2017-12-28 Integrin antagonists

Publications (1)

Publication Number Publication Date
CA3045491A1 true CA3045491A1 (en) 2018-07-19

Family

ID=62840040

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3045491A Abandoned CA3045491A1 (en) 2016-12-29 2017-12-28 Integrin antagonists

Country Status (14)

Country Link
US (1) US11306084B2 (enExample)
EP (1) EP3562826A4 (enExample)
JP (1) JP2020504120A (enExample)
KR (1) KR20190100232A (enExample)
CN (1) CN110177787A (enExample)
AU (1) AU2017393297A1 (enExample)
BR (1) BR112019012515A2 (enExample)
CA (1) CA3045491A1 (enExample)
CO (1) CO2019007023A2 (enExample)
IL (1) IL267686A (enExample)
MX (1) MX2019007797A (enExample)
PH (1) PH12019501514A1 (enExample)
RU (1) RU2019116820A (enExample)
WO (1) WO2018132268A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3045491A1 (en) 2016-12-29 2018-07-19 Indalo Therapeutics, Inc. Integrin antagonists
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
EP4159727B1 (en) 2017-02-28 2026-04-08 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
PT3844162T (pt) 2018-08-29 2025-03-28 Morphic Therapeutic Inc Inibidores da integrina alfa v beta6
AU2019327475B2 (en) 2018-08-29 2025-06-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
WO2024145245A2 (en) * 2022-12-27 2024-07-04 Pliant Therapeutics, Inc. Alpha-v-beta-8 integrin inhibitors and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004511434A (ja) * 2000-06-15 2004-04-15 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
MXPA05006588A (es) * 2002-12-20 2005-08-16 Pharmacia Corp Compuestos de pirazol como derivados antagonistas del receptor de la integrina.
BR0316876A (pt) 2002-12-20 2005-10-25 Pharmacia Corp Compostos de tiazol e composição farmacêutica compreendendo o mesmo
BR0317600A (pt) 2002-12-20 2005-11-29 Pharmacia Corp ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina
IN2015DN00099A (enExample) * 2012-07-18 2015-05-29 Univ Saint Louis
US8716226B2 (en) * 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
AU2017359028A1 (en) 2016-11-08 2019-06-20 Bristol-Myers Squibb Company Azole amides and amines as alpha V integrin inhibitors
CN110167934B (zh) 2016-11-08 2022-06-10 百时美施贵宝公司 作为αV整联蛋白抑制剂的含有环丁烷和含有氮杂环丁烷的单环和螺环化合物
EA201991123A1 (ru) 2016-11-08 2019-11-29 ИНДАЗОЛОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АНТАГОНИСТОВ ИНТЕГРИНА αV
EP3538528B1 (en) 2016-11-08 2020-12-23 Bristol-Myers Squibb Company Pyrrole amides as alpha v integrin inhibitors
PT3538525T (pt) 2016-11-08 2022-08-16 Bristol Myers Squibb Co Ácidos propiónicos 3-substituídos por inibidores de alfa v integrina
CA3045491A1 (en) 2016-12-29 2018-07-19 Indalo Therapeutics, Inc. Integrin antagonists
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
US20210284638A1 (en) 2018-07-03 2021-09-16 Saint Louis University ALPHAvBETA1 INTEGRIN ANTAGONISTS

Also Published As

Publication number Publication date
RU2019116820A (ru) 2021-01-29
WO2018132268A8 (en) 2019-06-20
CN110177787A (zh) 2019-08-27
AU2017393297A1 (en) 2019-06-13
JP2020504120A (ja) 2020-02-06
US11306084B2 (en) 2022-04-19
IL267686A (en) 2019-08-29
BR112019012515A2 (pt) 2019-11-19
WO2018132268A1 (en) 2018-07-19
EP3562826A4 (en) 2020-08-26
CO2019007023A2 (es) 2019-07-31
US20190345155A1 (en) 2019-11-14
PH12019501514A1 (en) 2020-09-14
EP3562826A1 (en) 2019-11-06
KR20190100232A (ko) 2019-08-28
MX2019007797A (es) 2019-10-21

Similar Documents

Publication Publication Date Title
KR102866916B1 (ko) Lpa 수용체 길항제 및 이의 용도
US11306084B2 (en) Integrin antagonists
TWI767410B (zh) 作為lpa受體拮抗劑之三唑胺基甲酸酯吡啶基磺醯胺及其用途
CN104640857B (zh) 作为整合素拮抗剂的β氨基酸衍生物
CN103534240B (zh) 选择性fak抑制剂
ES2383239T3 (es) Compuestos de ácidos policíclicos útiles como antagonistas de CRTH2 y como agentes antialérgicos
WO2020009889A1 (en) ALPHAvBETA1 INTEGRIN ANTAGONISTS
MXPA01012450A (es) Inhibidores de metaloproteasas.
KR20140040774A (ko) 이미다조피리딘 화합물
KR20180107121A (ko) 팬 인테그린 길항제로서의 메타-아자사이클릭 아미노 벤조산 유도체
TW202222770A (zh) 苄胺或苄醇衍生物及其用途
EA022646B1 (ru) Замещенное производное изохинолина
US8119673B2 (en) Compounds 148
JP2005255675A (ja) 医薬組成物
JP2019526564A (ja) Ｈｔｒａ１阻害剤としての新規なトリフルオロメチルプロパンアミド誘導体
WO2024121709A1 (en) Papain-like protease (plpro) inhibitors
GB2640329A (en) Hedgehog acyltransferase inhibitors
KR20160018557A (ko) TAFIa의 저해제로서의 마크로사이클릭 우레아 유도체, 이의 제법 및 의약품으로서의 이의 용도
HK1209749B (en) Beta amino acid derivatives as integrin antagonists
NZ753990A (en) Integrin antagonists

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220629